Mesenbio Information, Including Revenue, Investors, Funding, Competitors & Key Metrics

Mesenbio is a preclinical biopharmaceutical business based at the University of York. Its Cell Line Extracellular Vesicle Release (CLEVR) technique allows for a more diverse treatment pipeline by overcoming the most common hurdle in extracellular vesicle therapy.

Company Highlights
Year Founded

2021

icon-altEmployees

9

Location (HQ)

GBR

Since Last Funding

11 months

icon-altTotal Investment Amt

$1.8M

Last Funding Round

Seed

icon-altYoY Headcount Growth

193.55%

Key Metrics

Senior Hires

NameLinkedin ProfilePositionDate Joined
John Doehttps://www.linkedin.com/in/johndoeCEOCEO
Jane Doehttps://www.linkedin.com/in/janedoeCTOCTO
John Smithhttps://www.linkedin.com/in/johnsmithCFOCFO
Jane Smithhttps://www.linkedin.com/in/janesmithCOOCOO
Get API access to complete private company database with growth metrics from 15 sources

Biotechnology

Biotechnology Research